Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker ABVX · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet… NCT07453784 · Healthy Obefazimod 50 mg Capsule, Obefazimod Minitablet 50 mg | ABVX Abivax S.A. | Phase 1 | Recruiting | 44 | Apr 2027 | Registry ↗ |
| Nov 9, 2026 | Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464 NCT05121714 · Healthy Caffeine, ABX464 | ABVX Abivax S.A. | Phase 1 | Completed | 59 | May 18, 2021 | Registry ↗ |
| Sep 29, 2026 | ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma NCT03897543 · Carcinoma, Hepatocellular ABX196 | ABVX Abivax S.A. | Phase 1/2 | Completed | 10 | Apr 14, 2022 | Registry ↗ |
| Sep 10, 2026 | ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 NCT05507216 · Ulcerative Colitis ABX464, Placebo | ABVX Abivax S.A. | Phase 3 | Completed | 636 | Jun 24, 2025 | Registry ↗ |
| Sep 10, 2026 | ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 NCT05507203 · Ulcerative Colitis ABX464, Placebo | ABVX Abivax S.A. | Phase 3 | Completed | 639 | Jun 24, 2025 | Registry ↗ |
| Jul 7, 2026 | ABTECT - Maintenance NCT05535946 · Ulcerative Colitis ABX464, Placebo | ABVX Abivax S.A. | Phase 3 | Active, not recruiting | 1,116 | Apr 28, 2026 | Registry ↗ |
| May 6, 2026 | Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulce… NCT04023396 · Ulcerative Colitis ABX464 | ABVX Abivax S.A. | Phase 2 | Completed | 217 | Feb 23, 2023 | Registry ↗ |
| Apr 27, 2026 | Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease NCT06456593 · Moderately to Severely Active Crohn Disease Obefazimod, Placebo | ABVX Abivax S.A. | Phase 2 | Recruiting | 212 | Dec 2026 | Registry ↗ |
| Apr 27, 2026 | Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerati… NCT05177835 · Ulcerative Colitis ABX464 | ABVX Abivax S.A. | Phase 2 | Active, not recruiting | 203 | Mar 2028 | Registry ↗ |
| Nov 28, 2025 | Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis NCT03760003 · Ulcerative Colitis ABX464 100 mg, ABX464 50 mg | ABVX Abivax S.A. | Phase 2 | Completed | 355 | Apr 1, 2021 | Registry ↗ |
| Nov 26, 2025 | ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19 NCT04393038 · COVID-19 ABX464, Placebo | ABVX Abivax S.A. | Phase 2/3 | Terminated | 509 | Mar 5, 2021 | Registry ↗ |
| Nov 17, 2025 | Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rh… NCT04049448 · Rheumatoid Arthritis ABX464 | ABVX Abivax S.A. | Phase 2 | Completed | 40 | Jan 23, 2023 | Registry ↗ |
| May 29, 2025 | Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis NCT03368118 · Ulcerative Colitis ABX464 | ABVX Abivax S.A. | Phase 2 | Completed | 22 | Jul 12, 2022 | Registry ↗ |
| Sep 19, 2024 | ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment NCT02735863 · HIV Infection ABX464, Placebo | ABVX Abivax S.A. | Phase 2 | Completed | 30 | Aug 30, 2017 | Registry ↗ |
| Jul 31, 2024 | Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients NCT03905109 · Crohn Disease ABX464, Placebo | ABVX Abivax S.A. | Phase 2/3 | Withdrawn | 0 | Sep 19, 2022 | Registry ↗ |
| Jun 3, 2024 | ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis NCT03093259 · Ulcerative Colitis ABX464, Placebo oral capsule | ABVX Abivax S.A. | Phase 2 | Completed | 32 | Jul 25, 2018 | Registry ↗ |
| May 17, 2024 | ABX464 First in Man Study NCT02792686 · Healthy Volunteers ABX464 | ABVX Abivax S.A. | Phase 1 | Completed | 24 | Jul 2014 | Registry ↗ |
| Mar 31, 2023 | A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seroposi… NCT02990325 · HIV Infections, Health Volunteers ABX464 150mg, ABX464 50mg | ABVX Abivax S.A. | Phase 1/2 | Completed | 36 | Dec 27, 2018 | Registry ↗ |
| Feb 15, 2023 | Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis NCT03813199 · Rheumatoid Arthritis ABX464 50mg, Matching Placebo | ABVX Abivax S.A. | Phase 2 | Completed | 60 | Apr 27, 2021 | Registry ↗ |
| Jan 26, 2023 | Safety and Pharmacokinetics Study in Healthy Japanese Volunteers NCT05032560 · Healthy Volunteers ABX464, Placebo | ABVX Abivax S.A. | Phase 1 | Completed | 48 | Feb 18, 2022 | Registry ↗ |
| Jan 24, 2017 | Clinical Efficacy of ABX203 Therapeutic Vaccine in HBeAg Negative Patients With Chronic Hepatitis B NCT02249988 · Chronic Hepatitis B ABX203 therapeutic Hepatitis B vaccine treatment arm | ABVX Abivax S.A. | Phase 2/3 | Completed | 261 | Dec 2016 | Registry ↗ |
| May 30, 2016 | Safety, PK and PD Study of ABX464 in Untreated HIV Patients NCT02452242 · Human Immunodeficiency Virus Infections ABX464, Placebo | ABVX Abivax S.A. | Phase 2 | Completed | 70 | Dec 2015 | Registry ↗ |
| Apr 8, 2016 | Food Effect on Pharmacokinetic Parameters of ABX464 NCT02731885 · Healthy Volunteers ABX464 Single dose, ABX464 Repeated dose | ABVX Abivax S.A. | Phase 1 | Completed | 48 | Jun 2015 | Registry ↗ |
23 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:12 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances